Marie Williams
Nurse Practitioner · Carbondale, PANPI 1093706780
Payments from drug & device makers
Across 174 payments — averaging $19.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$752
- Johnson & Johnson$616
- Neurocrine Biosciences, Inc.$463
- Otsuka America Pharmaceutical, Inc.$439
- AbbVie$352
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$285
- plus $518 from 6 others
What the payments were for
- Speaking & faculty fees$2407%
- Food & beverage$3,07590%
- Education$1113%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 45 | $752 |
| Johnson & Johnson | 23 | $616 |
| Neurocrine Biosciences, Inc. | 28 | $463 |
| Otsuka America Pharmaceutical, Inc. | 24 | $439 |
| AbbVie | 21 | $352 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $285 |
| Intuitive Surgical | 2 | $240 |
| Vanda Pharmaceuticals Inc. | 7 | $143 |
| Axsome Therapeutics, Inc. | 4 | $68 |
| Sunovion Pharmaceuticals Inc. | 3 | $40 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Indivior Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,427 in reported general payments places this provider in the 90th percentile of 4,059 nurse practitioner providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 24 | $196,446 |
| Invega SustennaPaliperidone Palmitate | 47 | $155,451 |
| Austedo XrDeutetrabenazine | 14 | $92,805 |
| Clomipramine Hcl | 23 | $12,212 |
| Paliperidone ErPaliperidone | 40 | $11,955 |
| Lurasidone Hcl | 27 | $4,094 |
| Aripiprazole | 81 | $1,961 |
| Quetiapine Fumarate | 100 | $1,927 |
| Risperidone | 197 | $1,837 |
| Bupropion Hcl SrBupropion Hcl | 134 | $1,749 |
| Buspirone Hcl | 181 | $1,664 |
| Alprazolam | 241 | $1,585 |
| Clozapine | 28 | $1,366 |
| Divalproex Sodium | 23 | $1,310 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 83 | $1,036 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $463 | $196,44624 claims |
| Johnson & JohnsonInvega Sustenna | $616 | $155,45147 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $752 | $92,80514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,059 nurse practitioner providers in Pennsylvania.
Other nurse practitioner in Carbondale
- Patricia ManganPhiladelphia$360K
- Lisa CocoPhiladelphia$230K
- Elisabeth BaidalPhiladelphia$151K
- Suzanne McGettiganPhiladelphia$108K
- Tracey WileyChambersburg$101K
- Pamela LorditchJohnstown$81K
- Nana BernaskoHershey$81K
- Dawn JeanneratClarion$78K
- Carolyn GrandePhiladelphia$71K
- Nicole WaetzmanStrafford$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.